New PBAC advice on IBD drugs

The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended Authority Required listings for two new forms and strengths of adalimumab – 20mg in 0.2ml prefilled syringe and 80mg in 0.8ml prefilled pen. The change applies to a number of rheumatological and gastroenterological indications including severe Crohn’s disease, refractory fistulating Crohn’s disease and moderate to severe ulcerative ...

Already a member?

Login to keep reading.

© 2021 the limbic